Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group.

J Hepatol. 2005 Aug;43(2):250-7.

PMID:
16082736
2.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
3.

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.

Gastroenterology. 2009 Mar;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 Nov 19.

PMID:
19135998
4.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
5.

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.

Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M.

Gastroenterol Hepatol. 2014 Jan;37(1):1-8. doi: 10.1016/j.gastrohep.2013.10.005. Epub 2013 Dec 17.

PMID:
24360571
6.

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M.

Gastroenterology. 2010 Nov;139(5):1593-601. doi: 10.1053/j.gastro.2010.07.009. Epub 2010 Jul 14.

PMID:
20637202
7.

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.

Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM.

J Viral Hepat. 2010 Feb 1;17(2):139-47. doi: 10.1111/j.1365-2893.2009.01157.x. Epub 2009 Aug 5.

8.

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.

Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML.

Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40. Epub 2007 Dec 10.

9.

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.

Gastroenterology. 2005 Aug;129(2):522-7.

PMID:
16083709
10.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Hepatology. 2008 Jun;47(6):1884-93. doi: 10.1002/hep.22319.

PMID:
18508296
11.

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.

Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Gut. 2007 Apr;56(4):553-9. Epub 2006 Sep 6.

13.

[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].

Li MH, Chen LJ, Qiu GH, Lu Y, Xie Y, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):497-500. Chinese.

PMID:
19912682
14.

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team.

JAMA. 2004 Dec 15;292(23):2839-48.

PMID:
15598915
15.

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group.

J Hepatol. 2006 Feb;44(2):275-82. Epub 2005 Nov 7.

PMID:
16338019
16.
17.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

18.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.

Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators.

Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816.

PMID:
20683847
19.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

20.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10.

PMID:
19909752

Supplemental Content

Support Center